Forest plot representing survival analysis and the impact of the Fcγ receptor genotypes on PFS per treatment arm. (A) Patients with FL in the GALLIUM trial; (B) patients with DLBCL in the GOYA trial. Time to event was defined by PFS (in days). All analyses were unadjusted and unstratified. Variables for the univariate analysis included biomarker and treatment arm. P-value (for hypothesis testing of whether the biomarker effect was equal to 0) was calculated with the Wald test. Adjusted P-values were corrected for multiple comparisons by the Benjamini and Hochberg method. Adj, adjusted; G, obinutuzumab; R, rituximab.